Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kissei Kicks Off Japan PIII for Linzagolix in Uterine Fibroids
Kissei Pharmaceutical said on July 6 that it has launched a Japanese PIII clinical trial for its oral GnRH antagonist linzagolix (KLH-2109) for the treatment of uterine fibroids. The trial consists of two double-blind studies. One looks into the efficacy…
To read the full story
Related Article
- Kissei Files Linzagolix for Uterine Fibroids in Japan
February 27, 2025
- Kissei Clears Primary Goal for Linzagolix in Japan PIII
July 17, 2024
BUSINESS
- Sandoz Poaches Regeneron’s Yohei Ishii as Japan Chief
April 30, 2026
- Nipro to List Forxiga AG in June Ahead of Pricing Rule Shift
April 30, 2026
- FDA Accepts Zipalertinib NDA for EGFR Exon 20-Mutant Lung Cancer: Taiho
April 30, 2026
- Japan Drug Sales Top 11 Trillion Yen in FY2025, Keytruda Leads: Encise
April 30, 2026
- Taiho Moves Araris’ ADC into PI for Lymphoma in US
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…